New prospects in the use of Kadcyla® in breast cancer

New prospects in the use of Kadcyla® in breast cancer

As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poorprognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients with the disseminated forms of BC was 20 % (media...

Full description

Bibliographic Details
Main Authors: G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, R. M. Paltuev, E. E. Topuzov, T. Yu. Semiglazova, E. K. Zhil’tsova, R. V. Donskikh, T. T. Tabagua, V. S. Apollonova
Format: Article
Language:Russian
Published: ABV-press 2015-11-01
Series:Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:
her-2-positve breast cancer
metastatic breast cancer
targeted therapy
trastizumab
t-dm1
transtuzumab emtansine
kadcyla
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/458

Internet

https://ojrs.abvpress.ru/ojrs/article/view/458

Similar Items